Updated Aug 14 at 11:11am ET.
Follow Illumina to never miss an important update.
Illumina filed a report with the SEC, a government agency that tracks company disclosures, showing it has entered into new financial agreements and taken on new debt. The filing also notes that some previous material agreements have been ended.
These types of filings are routine when a company is reorganizing its finances or updating its borrowing terms. For a long-term owner, the focus remains on whether these changes help the company fund the rollout of its newest gene-sequencing machines, which are the primary driver of its future profits.
Source: 8-K filing
Canaccord Genuity raised its price target for the stock from $190 to $205. This adjustment follows the company's latest financial results, which showed growth in its core sequencing business. The new target suggests the firm sees more room for the stock to rise as customers adopt the newer NovaSeq X machines.
Source: Canaccord Genuity
RBC Capital raised its price target from $170 to $230, a jump of about 35 percent. The firm kept its outperform rating, which is a signal they expect the stock to do better than the broader market. This optimism likely stems from the company's ability to beat earnings expectations and raise its full-year outlook.
Source: RBC Capital
The company reported revenue of $1.16 billion, which was higher than the $1.13 billion analysts expected. Profits also came in ahead of schedule, with adjusted earnings of $1.31 per share. This growth was driven by strong demand for the NovaSeq X, the company's newest machine used to map DNA.
Management raised its financial goals for the rest of the year, signaling they are confident that labs will continue to spend on genetic research tools. This is a positive sign that the business is successfully moving past its recent corporate distractions and focusing on its core technology.
See the full quarter, and how our tracked metrics did
Source: 8-K filing
The company is buying out certain future payment obligations related to Standard BioTools. This move happens as Standard BioTools sells off part of its business to merge with Treeline Biosciences. For a long-term owner, this is a minor piece of financial housekeeping that simplifies the company's balance sheet by removing potential future costs.
Source: GlobeNewsWire
Analysts recently issued a flurry of price target increases following the company's latest earnings report. Most analysts, 26 of 50, rate the stock a buy, and the average target of $200 suggests about 5% room for growth.
Management has a very consistent habit of beating its own targets, clearing the bar in seven of the last eight quarters. This suggests they set conservative goals they know they can hit.
| Expectation | |
|---|---|
| EPS | $1.38 |
| Revenue | $1.15B |
